Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany-Reference-Cited by-同舟云学术

Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany

Published:2019-01 Issue:2 Volume:8 Page:121-131
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Mayerhoff Lukas¹,Lehne Moritz¹,Hickstein Lennart²,Salimullah Tayyab³,Prieur Sigurd¹,Thomas Simu K⁴,Zhang Jie⁴

Affiliation:

1. Elsevier Health Analytics, Berlin, Germany

2. Health Risk Institute, Berlin, Germany

3. Novartis Pharmaceuticals Corporation, Basel, Switzerland

4. Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA

Abstract

Aim: Quantify hematopoietic stem cell transplantation (HSCT) costs in German patients with acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Methods: The primary outcome was direct and indirect costs in patients with ALL/DLBCL/FL who received HSCT between 2010 and 2014. Costs were evaluated two to four quarters before to eight quarters after HSCT. Results: Among 258 patients with HSCT, direct costs were €290,125/patient (pediatric ALL), €246,266/patient (adult ALL), €230,399/patient (DLBCL/FL allogeneic) and €107,457/patient (DLBCL/FL autologous). Indirect costs with HSCT were €52,939/patient (adult ALL), €20,285/patient (DLBCL/FL allogeneic) and €29,881/patient (DLBCL/FL autologous). Conclusion: Direct and indirect costs associated with HSCT are substantial for patients with ALL, DLBCL and FL. Novel therapies that reduce HSCT use could reduce medical costs.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2018-0100

Reference20 articles.

1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality, and prevalence worldwide in 2012. Estimated age-standardised incidence and mortality rates: men (2012). http://globocan.iarc.fr/Pages/fact_sheets_population.aspx.

2. Hematopoietic Stem-Cell Transplantation

3. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

4. Acute lymphoblastic leukemia: a comprehensive review and 2017 update

5. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed diagnosis of ocular graft-versus-host disease after allogeneic hematopoietic stem cell transplantation;The Ocular Surface;2024-10

2. Follicular lymphoma or diffuse large B-cell lymphoma: a population based analysis of epidemiological and health economic aspects in Germany;2024-09-03

3. Healthcare Resource Utilization and Cost Associated with Allogeneic Hematopoietic Stem Cell Transplantation: A Scoping Review;Transplantation and Cellular Therapy;2024-05

4. Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis;Oncology and Therapy;2024-02-20

5. Perspectives on the Cost and Value of Stem Cell and Emerging Therapies;Comprehensive Hematology and Stem Cell Research;2024